XBIO - Xenetic Biosciences, Inc.
| Previous Close | 1.80 |
| Open | 1.81 |
| Bid | 1.40 x 1200 |
| Ask | 0.00 x 1000 |
| Day's Range | 1.81 - 1.93 |
| 52 Week Range | 1.59 - 4.49 |
| Volume | 5,836 |
| Avg. Volume | 12,742 |
| Market Cap | 16.215M |
| Beta | 1.66 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.41 |
| Earnings Date | Nov 13, 2017 - Nov 17, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.00 |
- Simply Wall St.•4 months ago
How Does Xenetic Biosciences Inc (NASDAQ:XBIO) Affect Your Portfolio Returns?
If you are looking to invest in Xenetic Biosciences Inc’s (NASDAQ:XBIO), or currently own the stock, then you need to understand its beta in order to understand how it canRead More...
- Simply Wall St.•4 months ago
Xenetic Biosciences Inc (NASDAQ:XBIO): Is Now The Time To Bet On Healthcare?
Xenetic Biosciences Inc (NASDAQ:XBIO), a USD$21.71M small-cap, is a healthcare company operating in an industry, which faces key trends such as rising demand fuelled by an aging population and theRead More...
- Simply Wall St.•5 months ago
Does Xenetic Biosciences Inc’s (NASDAQ:XBIO) CEO Pay Compared Well With Peers?
Jeff Eisenberg took the helm as Xenetic Biosciences Inc’s (NASDAQ:XBIO) CEO and grew market cap to $16.72M recently. Understanding how CEOs are incentivised to run and grow their company isRead More...
- Simply Wall St.•5 months ago
Who Really Owns Xenetic Biosciences Inc (XBIO)?
I am going to take a deep dive into Xenetic Biosciences Inc’s (NASDAQ:XBIO) most recent ownership structure, not a frequent subject of discussion among individual investors. Ownership structure has beenRead More...
- Simply Wall St.•6 months ago
Does Xenetic Biosciences Inc’s (XBIO) 83.8% Earnings Growth Make It An Outperformer?
Assessing Xenetic Biosciences Inc’s (NASDAQ:XBIO) past track record of performance is an insightful exercise for investors. It allows us to reflect on whether or not the company has met orRead More...
- Business Wire•6 months ago
Xenetic Biosciences Reports 2017 Third Quarter Financial Results and Provides Corporate Update
Xenetic Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today its unaudited financial results for the quarter ended September 30, 2017.
- Business Wire•7 months ago
Xenetic Biosciences Enters Into Sublicense Agreement Related to its PolyXen™ Technology with Baxalta Inc., a Wholly-owned Subsidiary of Shire plc
Xenetic Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today that it has entered into a Right to Sublicense Agreement with Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH , wholly-owned subsidiaries of Shire plc .
- Business Wire•7 months ago
Xenetic Biosciences Appoints Jeffrey F. Eisenberg as Chief Executive Officer
Xenetic Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today that it has appointed Jeffrey F.
- Simply Wall St.•8 months ago
How Should You Think About Xenetic Biosciences Inc’s (XBIO) Risks?
If you are a shareholder in Xenetic Biosciences Inc’s (NASDAQ:XBIO), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...
- Business Wire•8 months ago
Xenetic Biosciences Provides Update on Annual Meeting of Stockholders
Xenetic Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, today announced that its 2017 Annual Meeting of Stockholders , scheduled for Thursday, October 5, 2017, will be rescheduled to a later date in 2017.
- Business Wire•9 months ago
Xenetic Biosciences Announces Dismissal of Annual Meeting of Stockholders
Xenetic Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, today announced that its 2017 Annual Meeting of Stockholders , scheduled for Wednesday, August 16, 2017, was convened and dismissed, without any business being conducted, due to lack of the requisite quorum....
- Business Wire•9 months ago
Xenetic Biosciences Reports 2017 Second Quarter Financial Results and Provides Business Update
Xenetic Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today its unaudited financial results for the quarter ended June 30, 2017.
- Business Wire•9 months ago
Xenetic Biosciences Announces Appointment of Three Directors to the Board
Xenetic Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today that it has appointed Adam Logal, James E.
- Business Wire•10 months ago
Xenetic Biosciences Announces Adjournment of Annual Meeting of Stockholders until Wednesday, August 16, 2017
Xenetic Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, today announced that its 2017 Annual Meeting of Stockholders , scheduled for Tuesday, July 18, 2017, was convened and adjourned, without any business being conducted, due to lack of the requisite quorum.
- Business Wire•11 months ago
Xenetic Biosciences Commences Patient Enrollment in Phase 2 Study Evaluating XBIO-101 in Conjunction with Progestin Therapy for the Treatment of Endometrial Cancer
Xenetic Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, today announced that patient enrollment has commenced in its Phase 2 clinical study of XBIO-101 in conjunction with progestin therapy for the treatment of endometrial cancer, in a population of patients who ...
